vs
爵士制药（JAZZ）与TETRA TECH INC（TTEK）财务数据对比。点击上方公司名可切换其他公司
TETRA TECH INC的季度营收约是爵士制药的1.0倍（$1.2B vs $1.2B），爵士制药净利率更高（17.0% vs 8.7%，领先8.3%），爵士制药同比增速更快（10.1% vs -14.8%），爵士制药自由现金流更多（$345.8M vs $68.1M），过去两年爵士制药的营收复合增速更高（15.2% vs -1.6%）
爵士制药是一家全球性生物制药企业，核心业务聚焦肿瘤学与神经科学两大领域，2003年在美国加利福尼亚州成立，当前总部坐落于爱尔兰首都都柏林。
Tetra Tech Inc.是总部位于美国加利福尼亚州帕萨迪纳的咨询与工程服务企业，业务覆盖水资源、生态环境、基础设施、资源管理、能源、国际发展等领域，可提供专业咨询、工程设计、项目管理、施工管理等多元化专业服务。
JAZZ vs TTEK — 直观对比
营收规模更大
TTEK
是对方的1.0倍
$1.2B
营收增速更快
JAZZ
高出24.9%
-14.8%
净利率更高
JAZZ
高出8.3%
8.7%
自由现金流更多
JAZZ
多$277.7M
$68.1M
两年增速更快
JAZZ
近两年复合增速
-1.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.2B |
| 净利润 | $203.5M | $105.2M |
| 毛利率 | — | 18.2% |
| 营业利润率 | 21.2% | 11.6% |
| 净利率 | 17.0% | 8.7% |
| 营收同比 | 10.1% | -14.8% |
| 净利润同比 | 6.5% | 13424.7% |
| 每股收益（稀释后） | $3.34 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAZZTTEK
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $897.8M | $1.3B | ||
| Q4 24 | $1.1B | $1.4B | ||
| Q3 24 | $1.1B | $1.4B | ||
| Q2 24 | $1.0B | $1.3B | ||
| Q1 24 | $902.0M | $1.3B |
净利润JAZZTTEK
| Q4 25 | $203.5M | $105.2M | ||
| Q3 25 | $251.4M | $127.9M | ||
| Q2 25 | $-718.5M | $113.8M | ||
| Q1 25 | $-92.5M | $5.4M | ||
| Q4 24 | $191.1M | $778.0K | ||
| Q3 24 | $215.1M | $96.2M | ||
| Q2 24 | $168.6M | $85.8M | ||
| Q1 24 | $-14.6M | $76.4M |
毛利率JAZZTTEK
| Q4 25 | — | 18.2% | ||
| Q3 25 | — | 20.6% | ||
| Q2 25 | — | 18.4% | ||
| Q1 25 | — | 16.2% | ||
| Q4 24 | — | 15.6% | ||
| Q3 24 | — | 17.8% | ||
| Q2 24 | — | 16.6% | ||
| Q1 24 | — | 16.6% |
营业利润率JAZZTTEK
| Q4 25 | 21.2% | 11.6% | ||
| Q3 25 | 5.1% | 13.6% | ||
| Q2 25 | -65.6% | 12.0% | ||
| Q1 25 | -6.2% | 3.0% | ||
| Q4 24 | 17.5% | 1.6% | ||
| Q3 24 | 24.7% | 10.4% | ||
| Q2 24 | 19.5% | 9.6% | ||
| Q1 24 | 7.3% | 9.4% |
净利率JAZZTTEK
| Q4 25 | 17.0% | 8.7% | ||
| Q3 25 | 22.3% | 9.6% | ||
| Q2 25 | -68.7% | 8.3% | ||
| Q1 25 | -10.3% | 0.4% | ||
| Q4 24 | 17.6% | 0.1% | ||
| Q3 24 | 20.4% | 7.0% | ||
| Q2 24 | 16.5% | 6.4% | ||
| Q1 24 | -1.6% | 6.1% |
每股收益（稀释后）JAZZTTEK
| Q4 25 | $3.34 | $0.40 | ||
| Q3 25 | $4.08 | $0.48 | ||
| Q2 25 | $-11.74 | $0.43 | ||
| Q1 25 | $-1.52 | $0.02 | ||
| Q4 24 | $2.97 | $0.00 | ||
| Q3 24 | $3.42 | $-3.18 | ||
| Q2 24 | $2.49 | $1.59 | ||
| Q1 24 | $-0.23 | $1.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $269.4M |
| 总债务越低越好 | $5.4B | $837.1M |
| 股东权益账面价值 | $4.3B | $1.8B |
| 总资产 | $11.7B | $4.3B |
| 负债/权益比越低杠杆越低 | 1.24× | 0.45× |
8季度趋势，按日历期对齐
现金及短期投资JAZZTTEK
| Q4 25 | $1.4B | $269.4M | ||
| Q3 25 | $1.3B | $167.5M | ||
| Q2 25 | $1.2B | $242.8M | ||
| Q1 25 | $1.9B | $179.4M | ||
| Q4 24 | $2.4B | $248.1M | ||
| Q3 24 | $2.2B | $232.7M | ||
| Q2 24 | $1.4B | $212.3M | ||
| Q1 24 | $1.4B | $210.3M |
总债务JAZZTTEK
| Q4 25 | $5.4B | $837.1M | ||
| Q3 25 | $5.4B | $766.4M | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | $1.0B | ||
| Q4 24 | $6.1B | $888.5M | ||
| Q3 24 | $6.1B | $812.6M | ||
| Q2 24 | $5.7B | $861.8M | ||
| Q1 24 | $5.7B | $951.0M |
股东权益JAZZTTEK
| Q4 25 | $4.3B | $1.8B | ||
| Q3 25 | $4.0B | $1.8B | ||
| Q2 25 | $3.7B | $1.7B | ||
| Q1 25 | $4.2B | $1.6B | ||
| Q4 24 | $4.1B | $1.7B | ||
| Q3 24 | $4.2B | $1.8B | ||
| Q2 24 | $3.8B | $1.7B | ||
| Q1 24 | $3.7B | $1.6B |
总资产JAZZTTEK
| Q4 25 | $11.7B | $4.3B | ||
| Q3 25 | $11.4B | $4.3B | ||
| Q2 25 | $10.9B | $4.4B | ||
| Q1 25 | $11.5B | $4.2B | ||
| Q4 24 | $12.0B | $4.2B | ||
| Q3 24 | $12.3B | $4.2B | ||
| Q2 24 | $11.4B | $4.1B | ||
| Q1 24 | $11.3B | $4.1B |
负债/权益比JAZZTTEK
| Q4 25 | 1.24× | 0.45× | ||
| Q3 25 | 1.35× | 0.43× | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | 0.64× | ||
| Q4 24 | 1.49× | 0.53× | ||
| Q3 24 | 1.47× | 0.44× | ||
| Q2 24 | 1.52× | 0.52× | ||
| Q1 24 | 1.54× | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $362.5M | $72.3M |
| 自由现金流经营现金流 - 资本支出 | $345.8M | $68.1M |
| 自由现金流率自由现金流/营收 | 28.9% | 5.6% |
| 资本支出强度资本支出/营收 | 1.4% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.78× | 0.69× |
| 过去12个月自由现金流最近4个季度 | $1.3B | $497.5M |
8季度趋势，按日历期对齐
经营现金流JAZZTTEK
| Q4 25 | $362.5M | $72.3M | ||
| Q3 25 | $474.6M | $100.8M | ||
| Q2 25 | $88.9M | $349.6M | ||
| Q1 25 | $429.8M | $-5.8M | ||
| Q4 24 | $398.6M | $13.1M | ||
| Q3 24 | $398.7M | $105.6M | ||
| Q2 24 | $331.4M | $140.9M | ||
| Q1 24 | $267.2M | $102.9M |
自由现金流JAZZTTEK
| Q4 25 | $345.8M | $68.1M | ||
| Q3 25 | $459.4M | $95.6M | ||
| Q2 25 | $75.9M | $345.6M | ||
| Q1 25 | $415.9M | $-11.8M | ||
| Q4 24 | $385.3M | $9.6M | ||
| Q3 24 | $388.0M | $98.8M | ||
| Q2 24 | $324.3M | $137.1M | ||
| Q1 24 | $260.3M | $98.9M |
自由现金流率JAZZTTEK
| Q4 25 | 28.9% | 5.6% | ||
| Q3 25 | 40.8% | 7.2% | ||
| Q2 25 | 7.3% | 25.2% | ||
| Q1 25 | 46.3% | -0.9% | ||
| Q4 24 | 35.4% | 0.7% | ||
| Q3 24 | 36.8% | 7.2% | ||
| Q2 24 | 31.7% | 10.2% | ||
| Q1 24 | 28.9% | 7.9% |
资本支出强度JAZZTTEK
| Q4 25 | 1.4% | 0.3% | ||
| Q3 25 | 1.3% | 0.4% | ||
| Q2 25 | 1.2% | 0.3% | ||
| Q1 25 | 1.5% | 0.4% | ||
| Q4 24 | 1.2% | 0.2% | ||
| Q3 24 | 1.0% | 0.5% | ||
| Q2 24 | 0.7% | 0.3% | ||
| Q1 24 | 0.8% | 0.3% |
现金转化率JAZZTTEK
| Q4 25 | 1.78× | 0.69× | ||
| Q3 25 | 1.89× | 0.79× | ||
| Q2 25 | — | 3.07× | ||
| Q1 25 | — | -1.08× | ||
| Q4 24 | 2.09× | 16.79× | ||
| Q3 24 | 1.85× | 1.10× | ||
| Q2 24 | 1.97× | 1.64× | ||
| Q1 24 | — | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
TTEK
| Commercial International Services Group | $704.2M | 58% |
| Commercial | $225.4M | 19% |
| State And Local Government | $171.5M | 14% |
| Cost Plus | $95.1M | 8% |
| Related Party | $15.8M | 1% |
